The long-acting nebulizer was found to be less expensive and more convenient for older patients in comparison with Foradil, the dry-powder formulation drug for COPD.
The research conducted by Nicholas Gross, M.D., of the Hines VA Hospital in Chicago, and his colleagues determined that Perforomist may be a better alternative for COPD sufferers.
Their research was presented at the American Thoracic Society meeting at which they stated that "so far [Perforomist] is very safe and effective."
"Until recently, nebulized treatment for COPD was limited to short-acting bronchodilators requiring multiple administrations," said Dr. Gross.
It was found that Foradil, the dry-powder inhaler, required more of a challenge for these older patients in administering the drug to themselves. Although some patients may need assistance with the Perforomist nebulizer drug as well, it was found to be more convenient to administer.
According to Dr. Gross, Medicare covers the nebulizers but not the dry-powder inhalers, which may be another consideration for COPD patients.
However, the researchers noted that cardiac safety has been a concern with long-acting nebulizers/inhalers, but all research has been "very reassuring," according to Dr. Gross.
Overall, the study researchers believe that this drug will provide a new alternative with ease of use, lower cost, and long-acting results.
